0 results

    Ascendis Pharma

    Ascendis Pharma is an emerging speciality pharmaceutical company which creates improved, patentable versions of marketed drugs and high-value development-stage opportunities. The company operates within the therapeutic areas of endocrinology, central nervous system disorders and infectious diseases. The company is built upon a novel prodrug technology, TransCon, which conjugates peptides, proteins or small molecules to a carrier molecule in a reversible fashion. This unique reversibility allows an unmodified active drug to be released (unlinked) in the body in a precise, time-controlled fashion, creating a long-acting effect. Conventional conjugation technologies are unable to achieve this type of slow-release mechanism because the carrier molecule cannot de-link from the drug. Ascendis Pharma has seven high-value products in its portfolio, of which the lead program – TransCon PEG hGH – is a superior growth hormone with a once-weekly dosing regime, and this is part of the company’s specialty focus on endocrinology.The company is headquartered in Palo Alto, California and Copenhagen, Denmark. It also maintains research and clinical development sites in Heidelberg, Germany and Copenhagen, Denmark.


    The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

    SofinnovaMD Start

    The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.


    The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

    SofinnovaIndustrial Biotech

    Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.


    The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

    SofinnovaDigital Medicine

    The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.


    The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.